Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|November 13, 2015
The Genetic Evolution of Melanoma from Precursor LesionsA Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|August 29, 2022
Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)Florin Dobritoiu, Adelina Baltan, Alina Chefani, et al.
Cancer Research|April 19, 2005
Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoterSonia A Lee, Daniel Ndisang, Chandrakant Patel, et al.
Cancers|March 11, 2023
Inter- and Intra-Observer Agreement of PD-L1 SP142 Scoring in Breast Carcinoma-A Large Multi-Institutional International StudyMohamed Zaakouk, Mieke Van Bockstal, Christine Galant, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 11, 2025
A Global Ring Study: Concordance Between Ventana PATHWAY anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-low Breast CancerHans-Ulrich Schildhaus, Sunil Badve, Corrado D'Arrigo, et al.
Histopathology|February 23, 2026
Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA studyCorrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso-Sousa, et al.
Archives of Pathology & Laboratory Medicine|August 7, 2024
Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast CancerJosef Rüschoff, Alexander Penner, Ian O Ellis, et al.
Breast (Edinburgh, Scotland)|February 11, 2026
Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study resultsLazar Popovic, Romualdo Barroso-Sousa, Nagi S El Saghir, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry BiomarkersCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Pageof 4